Ferring Pharmaceuticals' CORTIMENT (budesonide), a treatment for ulcerative colitis indicated for the induction of remission in patients who have an active, mild to moderate form of the disease, recently received marketing approval by the European Union through the EU's Mutual Recognition Procedure. The drug was already available in the Netherlands since 2013, and the company now plans on launching it in 27 other European countries within the next few months.
CORTIMENT is a novel oral tablet formulation that contains the locally acting glucocorticosteroid budesonide, and uses the company's multi matrix colonic delivery technology. The drug is prescribed to be administered as a 9 mg tablet daily for up to eight weeks in adults. A phase III study revealed that between 2.4 to 3.9 times more patients were able to achieve clinical and endoscopic remission with CORTIMENT, in comparison to placebo. In addition, no clinically significant side effects were registered.